Sign in to continue:

Monday, October 20th, 2025

Thakral Corporation Updates 1HFY25 Financials With Revised GemLife Profit Impact—No Change to Shareholder Profit or Dividend Details 1

Thakral Corporation Ltd: 1HFY25 Updated Financial Results Analysis

On September 1, 2025, Thakral Corporation Ltd released an update to its unaudited financial results for the six months ended 30 June 2025 (1HFY25), reflecting revised impacts from its associate, GemLife Communities Group. This article presents a structured analysis of the updated report, key financial metrics, and strategic implications for investors.

Key Financial Metrics and Adjustments

The financial update was primarily driven by the late receipt of GemLife’s Q2FY25 results, which led to the recognition of an additional S\$1.679 million in share of profit from associates. This adjustment had a corresponding impact on the fair valuation of the investment in GemLife upon its IPO.

Metric 1HFY25 (Updated) 1HFY25 (Original) Change
Share of Profit from Associates S\$5.610 million S\$3.931 million +S\$1.679 million
Net Gain on Fair Valuation (before tax) S\$146.568 million S\$148.247 million -S\$1.679 million
Profit Attributable to Shareholders S\$109.325 million S\$109.325 million No change

Note: There is no mention of revenue, EPS, or dividends in the report. No year-over-year or quarter-over-quarter data is provided for these metrics.

Impact on Financial Position

  • No impact on the Group’s statements of financial position as at 30 June 2025.
  • No change to profit attributable to equity holders, earnings per share, deferred tax liability, or net asset value.

Exceptional Items & Asset Revaluation

  • The main exceptional item is the IPO-related fair value gain adjustment for the GemLife associate.
  • The share of profit adjustment was delayed due to late availability of associate results, but was promptly recognized upon receipt.

Chairman’s Statement

On behalf of the Board
Lim Swe Guan @ Lim Swee Guan
Independent Non-Executive Chairman
Singapore, 1 September 2025

Chairman’s Tone: The statement is factual and concise, with a neutral tone. There is no explicit commentary on the outlook or business environment.

Other Key Points

  • No mention of dividends, directors’ remuneration, share buybacks, placements, or significant corporate actions beyond the GemLife IPO-related fair value gain.
  • No discussion of macroeconomic, legal, or policy risks, nor any guidance on future performance.

Conclusion and Investor Recommendations

Overall Financial Performance: The Group’s 1HFY25 results remain robust with significant profit recognition from the GemLife IPO-related fair value gain. The update reflects responsible financial reporting, with timely recognition of associate profits. However, the lack of explicit discussion on recurring earnings, operational revenue, or forward-looking statements suggests a neutral outlook in terms of underlying business growth.

If you are currently holding this stock:
Consider maintaining your position. The company’s financials remain stable, with strong profit recognition from investment activities. However, monitor future disclosures for trends in operating performance, as the current results are heavily influenced by exceptional items rather than core business growth.

If you are not currently holding this stock:
Exercise caution before initiating a new position. The report highlights significant, but potentially non-recurring, earnings from asset revaluation rather than operational improvements. Await further updates on core business performance and more detailed financial disclosures.

Disclaimer: This analysis is based solely on information provided in the company’s 1HFY25 financial update. It does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.

View Thakral Historical chart here



ISEC Healthcare Reports 9% Net Profit Growth in 9M2024, Driven by Malaysian Expansion

Business Description: ISEC Healthcare Ltd. is a healthcare provider primarily operating in Malaysia and Singapore. The company operates through two main segments: Specialized Health Services: This segment, representing the majority of revenue, focuses on ophthalmology services....

Nanofilm Technologies 1H2025 Results: 30% Revenue Growth, S$95m Cash Balance, Interim Dividend of 0.33₵ per Share Announced 6

Nanofilm Technologies International 1H2025 Financial Results Analysis Nanofilm Technologies International has announced its results for the first half of 2025, showing a marked improvement in financial performance across all business units and a return...

Zhongxin Fruit and Juice Limited FY2025 Results: 76% Revenue Surge, No Dividend Declared for FY2025

Zhongxin Fruit and Juice Limited FY2025 Financial Analysis: Strong Revenue Growth Amid Uncertain Outlook Zhongxin Fruit and Juice Limited, a Singapore-listed subsidiary of China’s SDIC Zhonglu Fruit Juice Co., Ltd, has released its unaudited...